A ventilation-products manufacturer with a structural-growth tailwind, a specialty insurer and reinsurer, and a pioneering DNA-sequencing company bring three sharply different profiles to this FTSE 250 analysis. This piece assesses Volution, Lancashire and Oxford Nanopore against verified market data as at 14 September 2026, weighing quality compounding, insurance returns and frontier-technology growth.

FTSE 250 and UK market context

The FTSE 250 spans structurally growing manufacturers, specialty financial businesses and frontier-technology companies. These respond to very different forces — building regulation and the Demand for cleaner indoor air, insurance-pricing cycles, and the adoption of new scientific tools — making the index a way to assemble genuinely diversified exposures within the mid-cap market.

The month carries a scheduled index event. FTSE Russell announced its September 2026 quarterly review on 2 September, with changes effective from Monday 21 September 2026. Because announced changes take effect only on that date, the 14 September research date used here reflects the pre-review index. None of Volution, Lancashire or Oxford Nanopore appears among the September additions or deletions, so each remains a FTSE 250 constituent through the review.

The macro backdrop supports each differently. Volution benefits from structural demand for ventilation, driven by building regulations, energy efficiency and indoor-air-quality awareness, largely independent of the near-term cycle. Lancashire is driven by insurance-pricing conditions and the level of catastrophe and specialty risk. And Oxford Nanopore is geared to the adoption of its sequencing technology across research and applied markets. The recent easing in interest-rate expectations is broadly supportive, particularly for growth names.

Why these three stocks are attracting attention in September 2026

Volution is a leading supplier of ventilation products across the UK, continental Europe and Australasia, benefiting from structural drivers around indoor air quality and energy efficiency, and it has a strong record of growth through both organic expansion and acquisition. Lancashire Holdings is a specialty insurer and reinsurer, Underwriting property, energy, marine, aviation and other specialty risks, geared to insurance-pricing conditions. Oxford Nanopore is a pioneer of nanopore-based DNA and RNA sequencing technology, a frontier-technology growth company addressing large research and applied markets.

Their financial profiles diverge markedly. As at 14 September 2026, Volution traded on a mid-20s multiple reflecting its structural-growth quality, with a modest yield; Lancashire on a single-digit multiple with strong Earnings growth and a modest yield; and Oxford Nanopore was loss-making on a trailing basis, its case resting on future growth. Together they blend quality compounding, insurance returns and frontier-technology growth.

Volution Group (FAN) — LSE:FAN

Business model and market position

Volution Group (LSE:FAN) is a leading international supplier of ventilation products, serving residential and commercial markets across the UK, continental Europe and Australasia. Its products — including extractor fans, mechanical ventilation with heat recovery, and related systems — help buildings manage air quality, moisture and energy efficiency. The group is positioned at the intersection of several structural drivers: tightening building regulations around ventilation and energy performance, growing awareness of indoor air quality, and the drive to make buildings more energy-efficient, all of which support long-term demand for its products.

The group classifies within producer manufacturing. It has built a strong record of growth through a combination of organic expansion and a disciplined Acquisition strategy, acquiring and integrating ventilation businesses across its markets to build scale and geographic breadth. Its focus on higher-value, regulation-driven and energy-efficient products supports margins and aligns it with durable structural trends, distinguishing it from purely cyclical building-products manufacturers.

Financial performance and Shareholder returns

As at 14 September 2026, Volution shares traded at 651p, for a Market Capitalisation of approximately £1.28bn. The stock was valued on a trailing price-to-earnings multiple of around 25 times, with trailing Diluted Earnings per Share of roughly 25.6p. Trailing EPS had grown strongly, by around 29 per cent year on year on the data reviewed, reflecting both organic growth and the contribution of acquisitions. The trailing dividend Yield was modest at around 1.8 per cent, consistent with a quality compounder that reinvests for growth and acquisitions while paying a progressive dividend, and the shares carried a favourable consensus analyst stance.

Strategy, acquisitions and RNS watch

Volution's strategy is to grow organically by capturing structural demand for ventilation, to acquire and integrate complementary businesses, to focus on higher-value and energy-efficient products, and to expand geographically. Investors following the group through the London Stock Exchange's regulatory news service will focus on organic Revenue growth, the contribution and integration of acquisitions, margins, cash generation and the dividend. Building regulations, energy-efficiency requirements and indoor-air-quality trends are the key structural drivers, while the disciplined execution of its acquisition strategy is central to its growth model.

Competitive positioning

Volution's competitive strengths lie in its scale and breadth across ventilation markets, its focus on higher-value and regulation-driven products, and its proven acquisition and integration capability. Its geographic and product breadth reduces reliance on any single market, while its alignment with structural drivers — regulation, energy efficiency and air quality — supports durable demand. Its disciplined acquisition strategy has consistently added scale and capability, and its focus on higher-value products supports margins. It competes with other ventilation manufacturers, but its scale, breadth and structural positioning give it a strong position.

Recent developments and outlook

Volution has continued to combine organic growth with acquisitions to build a broader, more international ventilation business, and the strong growth in trailing earnings reflects the success of that model. The outlook rests on continued structural demand for ventilation, the disciplined execution of further acquisitions, and Margin management. As a structural-growth compounder trading on a premium multiple, Volution offers exposure to durable, regulation-driven demand and a proven growth model, though its premium rating means it is valued for continued delivery, and the integration of acquisitions and the health of construction and renovation markets are considerations to weigh.

Lancashire Holdings (LRE) — LSE:LRE

Business model and market position

Lancashire Holdings (LSE:LRE) is a specialty insurer and reinsurer, underwriting a range of specialty risks including property, energy, marine, aviation and terrorism, alongside reinsurance. Operating from Bermuda and London, it focuses on short-tail, specialty lines — risks that are complex, often large, and require specialist underwriting expertise. Its disciplined, opportunistic approach to underwriting — deploying capital when pricing is attractive and pulling back when it is not — is central to its model, allowing it to generate strong returns across the insurance cycle by underwriting more when rates are high and less when they are soft.

The group classifies within finance. Its fortunes are driven by insurance-pricing conditions (the "cycle"), the level of insured catastrophe and specialty losses, and its Investment returns. When specialty insurance and Reinsurance rates are high — often following significant industry losses that reduce capital and push up prices — Lancashire can deploy capital and earn attractive returns; its disciplined underwriting and specialty focus are designed to capitalise on such conditions while managing risk.

Financial performance and shareholder returns

As at 14 September 2026, Lancashire shares traded at 620.5p, for a market capitalisation of approximately £1.51bn. The stock was valued on a low trailing price-to-earnings multiple of around 6.4 times, with trailing diluted earnings per share of roughly 96.7p. Trailing EPS had grown strongly, by around 35 per cent year on year on the data reviewed, reflecting favourable underwriting conditions and returns. The trailing Dividend Yield stood at around 2.7 per cent; specialty insurers often supplement Ordinary Dividends with special distributions when returns are strong, so total capital returns can exceed the ordinary yield in favourable years, an important consideration for income assessment.

Strategy, underwriting and RNS watch

Lancashire's strategy is to underwrite specialty risks with discipline, deploying capital when pricing is attractive, managing risk carefully, and returning surplus capital to shareholders. Investors following the group through the London Stock Exchange's regulatory news service will focus on premium growth, underwriting margins (combined ratio), the level of catastrophe and specialty losses, investment returns, and capital returns including any special dividends. Insurance-pricing conditions are the dominant external driver, and the incidence of major insured losses can significantly affect results in any given period.

Competitive positioning

Lancashire's competitive strengths lie in its specialist underwriting expertise, its disciplined and opportunistic approach, and its nimble, focused model. Underwriting complex specialty risks requires deep expertise and judgement, and Lancashire's focus and discipline allow it to deploy capital selectively when conditions are attractive. Its relatively nimble scale enables it to respond quickly to changing pricing conditions, underwriting more when rates are high and less when they soften. It competes with other specialty insurers and reinsurers, but its discipline, expertise and focus have underpinned strong returns across the cycle.

Recent developments and outlook

Favourable specialty insurance and reinsurance pricing conditions have supported Lancashire's underwriting returns, contributing to the strong growth in trailing earnings. The outlook rests on the continuation of attractive pricing, the incidence of insured losses, and investment returns. As a disciplined specialty insurer trading on a low earnings multiple with the potential for special dividends, Lancashire offers exposure to attractive insurance-cycle returns, though its results are inherently exposed to the incidence of major catastrophe and specialty losses, which can be volatile, and to the eventual softening of pricing as capital returns to the market.

Oxford Nanopore Technologies (ONT) — LSE:ONT

Business model and market position

Oxford Nanopore Technologies (LSE:ONT) is a pioneer of nanopore-based sequencing, a technology that reads the sequence of DNA and RNA molecules by passing them through tiny protein pores. Its platforms — ranging from handheld devices to larger benchtop and high-throughput systems — offer distinctive advantages, including real-time results, long sequencing reads, portability and scalability, differentiating them from established sequencing technologies. The group sells sequencing devices and, importantly, consumables (the reagents and flow cells used in each run), giving it a razor-and-blades model in which growing an installed base of devices drives recurring consumables revenue.

The group classifies within electronic technology and addresses large and growing markets in scientific research, and increasingly in applied areas such as clinical, biopharma, agriculture and public health. As a frontier-technology company, it is in a growth phase, investing to expand adoption of its platforms and to develop new applications. Its distinctive technology and expanding applications underpin the long-term opportunity, though realising it requires converting technological promise into widespread, revenue-generating adoption.

Financial performance and what to watch

As at 14 September 2026, Oxford Nanopore shares traded at 156.9p, for a market capitalisation of approximately £1.53bn. The group was loss-making on a trailing basis, with negative trailing diluted earnings per share on the data reviewed, so a conventional price-to-earnings multiple is not applicable; this is typical of a frontier-technology growth company investing ahead of profitability. It paid no dividend, consistent with a growth-stage Business reinvesting to expand adoption, yet the shares carried a favourable consensus analyst stance, reflecting the market's focus on revenue growth, adoption and the long-term opportunity rather than trailing losses.

Strategy, adoption and RNS watch

Oxford Nanopore's strategy is to grow the installed base of its sequencing platforms, drive recurring consumables revenue, expand into applied and clinical markets, and continue to innovate. Investors following the group through the London Stock Exchange's regulatory news service will focus on revenue growth, the growth of the installed base and consumables, progress in applied and clinical markets, gross margins, cash position and the path towards profitability. Adoption of its technology — particularly in higher-value applied and clinical applications — and the trajectory towards profitability are the key considerations.

Competitive positioning

Oxford Nanopore's competitive strengths lie in its distinctive technology, its intellectual property, and the unique capabilities of its platforms — real-time results, long reads, portability and scalability. These attributes differentiate it from established sequencing technologies and open applications that others cannot easily address. Its razor-and-blades model means a growing installed base drives recurring consumables revenue. It competes with established sequencing companies with greater scale and resources, so continued innovation and the expansion of adoption, particularly in higher-value applications, are central to its competitive position and to realising its long-term potential.

Recent developments and outlook

Oxford Nanopore continues to invest in expanding adoption of its sequencing platforms and in developing new applications across research, clinical and applied markets. The outlook rests on growing revenue and the installed base, expanding into higher-value applications, and progressing towards profitability. As a frontier-technology growth company that is loss-making on a trailing basis, it offers exposure to a distinctive, potentially transformative technology and large markets, but with the higher risk inherent in a business whose case rests on future adoption and profitability rather than current earnings; the path to profitability and the pace of adoption will be closely watched.

Comparison of the three companies

The trio spans quality compounding, insurance returns and frontier-technology growth. Volution is the structural-growth compounder: a ventilation manufacturer on a premium multiple with strong earnings growth, geared to durable regulation-driven demand. Lancashire is the insurance-cycle play: a disciplined specialty insurer on a low multiple with strong earnings growth and the potential for special dividends, geared to favourable pricing. Oxford Nanopore is the frontier-technology play: a loss-making but distinctive sequencing pioneer, geared to future adoption and the long-term opportunity.

The right valuation lens differs for each. Volution should be judged on its structural growth and execution, where its premium multiple reflects quality and reliability. Lancashire should be judged on its underwriting returns and capital generation across the cycle, where its low multiple reflects the cyclicality and loss-exposure of insurance. Oxford Nanopore should be judged on revenue growth, adoption and the path to profitability, since trailing earnings are not meaningful for a business at its stage.

For portfolio construction, the three offer genuinely diversifying exposures. Volution's returns are driven by building regulation and structural demand; Lancashire's by insurance pricing and losses; and Oxford Nanopore's by technology adoption. These drivers are largely uncorrelated, so an investor holding all three would spread risk across manufacturing, insurance and technology. All three remain FTSE 250 constituents through the September review, offering a spread from quality compounding to insurance returns to frontier-technology growth.

Key opportunities and potential catalysts

Volution's catalysts are continued structural demand, value-accretive acquisitions and margin progression. Lancashire's opportunities lie in favourable insurance-pricing conditions, disciplined underwriting and strong capital returns, including potential special dividends. Oxford Nanopore's catalysts are strong revenue and installed-base growth, progress in applied and clinical markets, and evidence of a path towards profitability.

Structural and cyclical drivers support the trio in different ways: regulation and energy efficiency underpin Volution regardless of the economic cycle; favourable pricing and, paradoxically, the aftermath of industry losses can benefit Lancashire; and the adoption of sequencing technology drives Oxford Nanopore over the long term. An easing interest-rate environment would broadly support growth names such as Volution and Oxford Nanopore. The diversity of these catalysts means the three are complementary rather than substitutable.

Key risks

Volution is exposed to the health of construction and renovation markets, the integration of acquisitions, and its premium valuation, which leaves little room for disappointment. Lancashire is exposed to the incidence of major catastrophe and specialty losses, the softening of insurance pricing, and investment returns. Oxford Nanopore is exposed to the pace of adoption, its cash position and path to profitability, and competition from established sequencing companies. Broad macroeconomic and, for Oxford Nanopore, research-funding conditions bear on the trio, with the insurer most exposed to loss events and the technology company to adoption and funding.

What investors may watch through the remainder of September 2026

Through late September, the FTSE reshuffle effective 21 September 2026 will influence mid-cap flows generally, though none of these companies is directly affected. Company-specific attention will focus on Volution's organic and acquisition-led growth, Lancashire's underwriting and any commentary on pricing and losses, and Oxford Nanopore's revenue and adoption trends, all via the London Stock Exchange's regulatory news service. Prices and valuations quoted here are as at 14 September 2026 and should be re-verified against live data before any decision.

Conclusion

Volution, Lancashire and Oxford Nanopore illustrate three distinct propositions within the FTSE 250: a structural-growth ventilation compounder, a disciplined specialty insurer geared to the insurance cycle, and a frontier-technology sequencing pioneer. As at 14 September 2026 each offered a different balance of growth, cyclical return and technological opportunity, and each remains in the index through the September review. The appropriate choice depends on whether an investor prioritises structural compounding, insurance-cycle returns or frontier-technology growth — and on their tolerance for the specific risks each entails, including the loss-exposure of insurance and the adoption risk of frontier technology.